Formation of particulate lipid lyotropic liquid crystalline nanocarriers using a microfluidic platform

[Display omitted] Non-lamellar lyotropic liquid crystal nanoparticles (LLCNPs) are gaining significant interest in the fields of drug delivery and nanomedicine. Traditional, top-down formulation strategies for LLCNPs are typically low-throughput, can lack controllability and reproducibility in the p...

Full description

Saved in:
Bibliographic Details
Published in:Journal of colloid and interface science 2023-03, Vol.634, p.279-289
Main Authors: Yu, Haitao, Dyett, Brendan P., Zhai, Jiali, Strachan, Jamie B., Drummond, Calum J., Conn, Charlotte E.
Format: Article
Language:English
Subjects:
Cubosomes
Drug delivery
Lipid lyotropic liquid crystalline nanocarriers
Liquid Crystals - chemistry
Microfluidic system
Microfluidics
Monoolein
Nanoparticles - chemistry
Particle Size
Polyethylenes - chemistry
Reproducibility of Results
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Non-lamellar lyotropic liquid crystal nanoparticles (LLCNPs) are gaining significant interest in the fields of drug delivery and nanomedicine. Traditional, top-down formulation strategies for LLCNPs are typically low-throughput, can lack controllability and reproducibility in the particle size distribution, and may be unsuitable for loading more fragile therapeutics. The development of a controllable, reproducible, scalable, and high-throughput strategy is urgently needed. Monoolein (MO)-based LLCNPs with various stabilizers (F127, F108, and Tween 80) and phytantriol (PT)-F127 cubosomes were produced at various flow conditions via a bottom-up method using a microfluidic platform. This simple enabling strategy was used to formulate LLCNPs with lower polydispersity compared to the traditional top-down homogenization method. Significantly, particle size could be quantitatively controlled by varying the overall flow-rate; a scaling law was identified between nanoparticle mean size and the total flow rate (Q) of meansize∼Q-0.15 for MO cubosomes and meansize∼Q-0.19 for PT cubosomes (at a fixed flow rate ratio). Effective size control was achieved for a range of cubosome formulations involving different lipids and stabilizers. The formulation of stable, drug-loaded cubosomes with high encapsulation efficiency using this method was exemplified using calcein as a model drug. This work will further promote the utilisation of LLCNPs in nanomedicine and facilitate their clinical translation.
ISSN:0021-9797
1095-7103
DOI:10.1016/j.jcis.2022.12.028